BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
Portfolio Pulse from
Kahn Swick & Foti, LLC is investigating the proposed sale of bluebird bio, Inc. to Carlyle Group and SK Capital Partners. The deal offers bluebird shareholders $3.00 per share in cash and a contingent value right of $6.84 per share.
March 13, 2025 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kahn Swick & Foti, LLC is investigating the proposed sale of bluebird bio, Inc. to Carlyle Group and SK Capital Partners. The deal offers bluebird shareholders $3.00 per share in cash and a contingent value right of $6.84 per share.
The investigation by Kahn Swick & Foti, LLC into the sale of bluebird bio, Inc. could impact the perception of the deal's fairness and adequacy, potentially affecting shareholder sentiment and stock price stability. However, the investigation itself does not immediately alter the terms of the deal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100